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Helena	Scully, Technological University Dublin 




is	 essential	 if	 pharmaceutical	 companies	 are	 to	 achieve	 the	 flexible	 regulatory	 approaches	
envisioned	by	 ICH	Quality	 guidelines,	 the	most	 recent	 being	 for	 post-approval	 changes	 as	 per	 ICH	
Q12.		While	self-inspection	has	the	potential	to	be	a	useful	tool	in	achieving	this	demonstration,	the	























that	 	 companies	 proactively	 approach	 regulators	 to	 consider	 applying	 for	 such	 relief	 as	
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To	 address	 this,	 Dr	 Kevin	O’Donnell	 	 from	 the	 Irish	 Health	 Products	 Regulatory	 Authority	
(HPRA)	presented	a	potential	model	for	demonstrating	the	effectiveness	of	the	PQS	from	a	
Quality	Risk	Management	(QRM)	perspective	(Greene	et	al.,	2019).		The	model	is	based	on	
‘successful	 integration	 of	 QRM	 with	 the	 four	 key	 elements	 of	 the	 PQS’	 as	 per	 ICH	 Q10:	
Process	 Performance	 and	 Product	 Quality	 Monitoring	 (PPPQM),	 Change	 Management,	
Corrective	 and	 Preventive	 Action	 (CAPA)	 and	 Management	 Review;	 together	 with	 the	
demonstration	of	the	application	of	the	two	principles	of	Quality	Risk	Management	(QRM)	
as	 per	 ICH	 Q9:	 that	 the	 evaluation	 of	 the	 risk	 to	 quality	 should	 be	 based	 on	 scientific	
knowledge	and	ultimately	link	to	the	protection	of	the	patient;	and	that	the	level	of	effort,	
formality	 and	 documentation	 of	 the	 quality	 risk	 management	 process	 should	 be	




















during	 the	 period	 in	 which	 self-inspection	 was	 reviewed,	 a	 deficiency	 relating	 to	 self-
inspections	 was	 found	 (O’Mahony	 2019).	 	 The	 majority	 of	 these	 deficiencies	 were	
categorised	under	‘QRM’	and	‘Procedure’,	with	‘Management	Commitment’	not	far	behind,	






with	 obvious	 deficiencies	 being	 found	 in	 regulatory	 inspections	 that	 should	 have	 been	













This	 study	was	 carried	 out	 between	 June	 and	 November	 2020	 as	 part	 of	 the	Masters	 of	
Science	 programme	 in	 Pharmaceutical	 Quality	 Assurance	 at	 Technological	 University	 (TU)	
Dublin.	The	outputs	of	the	study	were	as	follows:	
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Looking	 first	 at	 the	 EU	 GMP	 requirements,	 it	 was	 found	 that	 while	 the	 PQS	 is	 cited	
throughout	 most	 chapters	 of	 the	 European	 Union	 (EU)	 Good	 Manufacturing	 Practices	
(GMPs),	Chapter	1	deals	exclusively	with	the	core	elements	of	the	PQS	which	 includes	the	
requirement	 for	 implementing,	documenting	and	monitoring	 the	effectiveness	of	 the	PQS	
(European	 Commission,	 2019).	 Amongst	 other	 requirements	 in	 the	 chapter,	 it	 specifically	
states	that:	
	
“A	 Pharmaceutical	 Quality	 System	 appropriate	 for	 the	 manufacture	 of	 medicinal	
products	should	ensure	that	there	is	a	process	for	self-inspection	and/or	quality	audit,	




used	 to	appraise	 the	effectiveness	and	applicability	of	 the	PQS.	 	 In	 fact,	 the	most	notable	
finding	 of	 this	 review	 is	 the	 significant	 lack	 of	 detail	 in	 Chapter	 9.	 	 It	 consists	 of	 only	 4	
paragraphs;	an	introductory	sentence	and	three	listed	requirements:	self-inspections	should	
4






be	 scheduled	 according	 to	 a	 programme,	 conducted	 in	 an	 independent	 manner,	
documented,	 and	 the	 purpose	 of	 which	 is	 to	 ensure	 compliance	 with	 GMP	 and	 quality	






quality	 system	 effectiveness,	 internal	 audits	 or	 self-inspection	 in	 the	 US	 Food	 &	 Drug	
Administration	 (FDA)	 requirements	CFR	210	and	211	 (FDA,	2019a;	 FDA,	2019b).	However,	
FDA’s	 guidance	 document	 entitled	 ‘Quality	 Systems	 Approach	 to	 Pharmaceutical	 Current	
Good	Manufacturing	 Practice	 Regulations’	 does	 detail	 the	 requirement	 for	maintaining	 a	
‘robust’	quality	system,	along	with	the	requirement	to	conduct	internal	audits	stating:	
“A	quality	systems	approach	calls	for	audits	to	be	conducted	at	planned	intervals	to	
evaluate	 effective	 implementation	 and	 maintenance	 of	 the	 quality	 system	 and	 to	
determine	 if	 processes	 and	 products	 meet	 established	 parameters	 and	
specifications.”(FDA,	2006)	
While	 some	of	 the	detail	 is	 similar	 to	 that	 found	 in	Chapter	 9	 of	EudraLex	Volume	4,	 the	
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The	 literature	 review	highlighted	 the	 lack	of	 guidance	 in	 the	 regulatory	 requirements	and	






A	study	was	conducted	 to	 identify	examples	of	 industry	best	practices	 for	 ‘Demonstrating	
Effectiveness	 of	 the	 PQS	 from	 the	 perspective	 of	 QRM’,	 as	 per	 the	 model	 presented	 by	
O’Donnell,	 by	 two	 Pharmaceutical	 MSc.	 classes	 in	 TU	 Dublin.	 	 	 These	 studies	 were	
performed	 by	 six	 peer	 focus	 groups	 of	 eight	 part-time	 MSc.	 students	 made	 up	 of	 a	
combination	 of	 ‘Pharmaceutical	 Quality	 Assurance	 and	 Regulation’	 and	 ‘Pharmaceutical	
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effectiveness.	 	 This	 review	 gave	 the	 authors	 access	 to	 case	 studies	 from	 a	 number	 of	
different	companies	and	sectors	of	the	pharmaceutical	and	medical	device	industry,	giving	a	
good	reach	within	the	context	of	the	research	topic.		
The	 findings	 from	 the	 focus	 group	 review	 initiated	 the	 development	 of	 ‘Internal	 Audit	






Three	 interviews	were	carried	out	during	 the	autumn	of	2020,	 two	with	GMP	 Inspectors	 from	the	











about	 compliance,	 not	 about	 adding	 value	 to	 a	 company.	 	 The	 regulator’s	 approach	 to	 self-
inspection	was	cited	as	a	possible	reason	for	this	lack	of	improvement	by	each	interview	candidate.		
Regulators	spend	little	time	on	self-inspection,	it	 is	not	even	examined	in	some	audits.	 	Where	it	 is	
reviewed,	 it	 is	 seen	 as	 low-risk	 and	 is	 a	 cursory	 check	 for	 a	 procedure,	 schedule	 and	 schedule	
adherence.	 	 Additionally,	 a	 significant	 contributor	 to	 the	 status	 of	 self-inspection	 programmes	 in	
7
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industry	relates	 to	 the	 lack	of	detail	and	change	to	Chapter	9	of	 the	EU	GMPs,	as	 identified	 in	 the	
literature	review.		
	











Management	 focus	 tends	 to	 be	 concentrated	 on	 six	 sigma,	 Operational	 Excellence	 (OpEx),	 and	
similar	projects,	with	little	value	placed	on	improvements	that	could	be	gained	from	having	a	well-
functioning	 self-inspection	 system.	 	 It	 would	 be	 of	 benefit	 if	 management	 could	 refocus	 on	
programmes	such	as	self-inspection	which	may	improve	quality,	and	subsequently	reduce	corrective	
costs,	i.e.	the	more	hidden	costs	of	poor	or	‘non’-quality.		This	could	start	by	dedicating	a	responsible	
person	at	Management	 level	 for	overseeing	self-inspection.	 	Management	support	and	seniority	 is	







as	 they	 may	 not	 yet	 have	 the	 level	 of	 expertise	 required	 to	 properly	 challenge	 procedures.	 	 As	
processes	become	increasingly	complex	and	automated,	it	will	only	become	harder	for	companies	to	
adequately	 inspect	themselves.	 	Using	experts	from	sister	sites	may	be	beneficial	to	overcome	this	











For	 the	 programme	 to	 have	 value,	 it	 must	 move	 away	 from	 simply	 validating	 compliance	 to	
procedures	 and	 needs	 to	 be	 refocused.	 	 The	 following	 proposals	 were	 made	 by	 the	 interview	
candidates:		
• Reframe	self-inspection	as	an	opportunity	for	risk	identification	and	improvement.				
• Re-emphasise	 self-inspection	 as	 a	 cost-reduction	 programme	 by	 capturing	 trends	 and	
deficiencies	that	could	later	lead	to	non-conformances	in	regulatory	inspections,	or	recalls.	
• Take	a	more	competency-based	approach.	 	Area	or	process	owners	could	be	asked	to	self-










about	 identifying	 opportunities	 for	 continuous	 improvement	 and	 using	 it	 as	 a	 risk	
identification	tool,	which	would	 in	turn	trigger	the	risk	management	process.	 	Additionally,	
the	 risk	 register,	 risk	 assessments,	 and	 similar	 PQS	 documents,	 should	 show	 that	 audit	
findings	were	considered.		Evidence	for	such	is	not	seen	at	present.			
• A	 sense	 of	management	 commitment	 could	 be	 imparted	 through	 proactive	 presenting	 of	
metrics	boards,	meaningful	 improvement	projects,	and	management	review.	 	 It	was	noted	
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the	 approach	 that	 regulators	 would	 take.	 	 Further,	 having	 a	 patient	 centric	 focus	 throughout	 an	
internal	audit	would	serve	to	align	the	approaches	taken	to	internal	and	external	audits,	by	ensuring	








amalgamated	 to	 develop	 a	 process	 outline,	 or	 ‘roadmap’	 for	 a	 self-inspection	 process	 that	 if	
implemented	 may	 serve	 to	 demonstrate	 PQS	 effectiveness.	 	 An	 outline	 of	 the	 self-inspection	
roadmap	 is	 provided	 in	 Figure	 2,	 the	 steps	 of	 which	 are	 discussed	 in	 this	 section.	 	 In	 addition,	 5	
checklists	were	generated	from	the	research	findings	that	could	be	used	for	an	internal	audit	of	the	
self-inspection	process	itself	and	the	4	PQS	elements	as	per	ICH	Q10.		These	checklists	are	presented	
in	an	appendix	 to	 this	paper.	 	 The	main	 intention	of	 the	 roadmap	and	checklists	 is	 to	ensure	 that	
QRM	 and	 management	 commitment	 are	 embedded	 throughout	 the	 self-inspection	 and	 the	 PQS	
























A	dedicated	 ‘responsible	 person’	 from	 the	quality	 unit	 should	be	 assigned	 to	oversee	 and	
drive	the	entire	self-inspection	process.	 	This	person	should	be	of	suitable	seniority	and	at	
management	 level	 within	 the	 company.	 	 Top	 management	 should	 give	 that	 person	 the	
freedom	to	evolve	and	improve	the	process.		It	must	be	ensured	that	the	responsible	person	
has	 appropriate	 training,	 qualification	 and	 understanding	 of	 the	 requirements	 for	 self-
inspection	to	be	effective.				
	
The	 responsible	 person	 should	 oversee	 a	 cross-functional	 team	 of	 internal	 auditors	 and	










items	 listed	 in	 Chapter	 9	 of	 the	 EU	 GMPs	 need	 to	 be	 included	 in	 some	 capacity,	
organisations	should	consider	expanding	the	scope	of	processes	to	be	audited.		For	example,	
the	 four	 elements	of	 the	PQS	 should	 also	be	 included,	 suggested	 checklists	 for	which	 are	
provided	 in	 the	 Appendix	 to	 this	 paper.	 	 Additionally,	 other	 examples	 to	 consider	 for	
inclusion	 are	 supplier	 qualification	 and	 management,	 data	 integrity,	 process	 design	 and	
development,	performance	of	mock	recalls,	and	interactions	between	outsourced	activities	
and	 the	marketing	 authorisation	 holder.	 	 Ultimately,	 the	 processes	 to	 be	 audited	will	 be	
dependent	on	the	structure	of	the	organisation.			
	
A	 number	 of	 documents	 may	 aid	 in	 this	 step.	 	 SOPs	 or	 similar	 procedural	 and/or	 policy	
documents	 are	 likely	 already	 available	 for	many	 or	 all	 processes,	 and	 this	will	 be	 a	 good	
starting	 point.	 	 Additionally,	 process	 maps	 and	 process	 flow	 diagrams	 may	 already	 be	
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available	 for	manufacturing	processes	 and	 some	utilities.	 	While	outside	 the	 scope	of	 the	
self-inspection	 process,	 an	 additional	 prerequisite	 that	 may	 be	 beneficial	 is	 to	 generate	
process	maps	of	the	processes	to	be	audited	as	per	ISO	9001:2015	(ISO,	2015).		These	maps	
should	 demonstrate	 the	 inputs	 and	 outputs,	 the	 steps	 of	 the	 process,	 interactions	 with	
other	processes,	resources	and	responsibilities,	and	methods	of	measuring	and	monitoring	






then	 be	 categorised	 and	 prioritised	 for	 self-inspection	 based	 on	 their	 associated	 risk.	 	 A	
suggested	method	to	consider	when	defining	the	programme	is:	
	
a.	 Gather	 all	 useful	 data	 from	 activities	 already	 performed	 at	 the	 site.			


































b.	 Further	 define	 the	 scope	 using	 risk	 assessments	 already	 performed.			
Specific	elements	of	the	process	that	are	considered	to	have	an	inherently	‘high’	risk	
associated	 with	 them	 and	 their	 control	 measures,	 or	 those	 with	 a	 high	 level	 of	
residual	 risk,	may	 be	 included.	 	 Conversely,	 depending	 on	 the	 risk,	 it	 may	 not	 be	
necessary	 to	 audit	 all	 steps	 or	 control	 points	 within	 a	 process.	 	 	 For	 example,	
elements	 of	 the	 process	 that	 are	 lower	 risk	 or	 are	 considered	 to	 be	 in	 a	










Only	 objective	 evidence	 should	 be	 considered	 and	 relied	 upon	 for	 satisfying	 the	 audit	
criteria.		All	audit	findings	should	be	documented	with	reference	to	the	objective	evidence	
13
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a.	 Immediately	 following	 the	 audit,	 the	 risk	 evaluation	 performed	 during	 Step	 3,	
‘Define	the	programme’	should	be	assessed	and	updated	if	required.	It	may	also	be	




If	 non-conformances	are	 identified,	 they	 should	be	assigned	a	 level	of	 criticality	 in	
order	 to	establish	how	 they	 should	be	managed,	 the	extent	and	magnitude	of	 the	
non-conformity	 should	 be	 commensurate	 with	 the	 investigation	 and	 correction	
and/or	prevention.	 	This	 criticality	determination	should	 include	 risk	assessment	 in	




Some	 audit	 findings	 may	 be	 recommendations	 for	 improvements.	 	 Of	 particular	
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The	 audit	 findings	 should	 be	 an	 input	 into	 the	management	 review	 process.	 	 The	
internal	audit	report	should	provide	key	information	on	the	status	of	a	process	that	





A	 number	 of	 Key	 Performance	 Indicators	 (KPIs)	 may	 be	 reviewed	 that	 indicate	 the	 self-
inspection	programme	is	operating	effectively	and	these	are	given	in	Figure	2.		An	internal	
audit	 of	 the	 self-inspection	 process	 itself	 should	 also	 be	 undertaken	 to	 appraise	 its	






questions	 to	 be	 considered	 by	 the	 auditor	 during	 the	 internal	 audit	 that,	 when	 checked,	







‘tick-the-box’	 exercises.	 	 While	 it	 is	 important	 to	 ensure	 that	 there	 are	 documented	
procedures	 in	 place,	 there	must	 also	 be	 consideration	 of	 the	 content	 of	 those	 procedures.	 	 A	
review	of	decisions	made	 should	be	performed,	whether	 that	be	as	an	acceptance	of	 the	 residual	
risk	in	a	risk	assessment,	stating	that	a	process	is	in	a	state	of	control	following	a	PQR,	a	prioritisation	
of	 a	 CAPA	 implementation,	 or	 the	 decision	 not	 to	 implement	 a	 change	 proposal,	 to	 name	 a	 few.		
While	 it	 is	not	specifically	 itemised	 in	the	checklists,	reviewing	decisions	 in	this	way	 is	both	a	good	
QRM	 and	 KM	 review	 exercise.	 	 The	 auditors	 are	 assessing	 whether	 the	 decisions	 taken	 were	
appropriate	and	effective,	based	on	objective	evidence.		The	capturing	and	review	of	these	decisions	
16
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are	 not	 typically	 looked	 at	 by	 regulatory	 authorities	 during	 inspection	 (FDA,	 2006;	 EMA,	
2010).	 	 Furthermore,	 there	 is	 currently	 little	 time	 spent	 on	 reviewing	 the	 self-inspection	
process	during	regulatory	 inspections,	due	to	other	areas	 taking	priority.	 	Thus,	 relying	on	
presenting	 internal	audit	 reports	 to	 the	regulator	 to	demonstrate	PQS	effectiveness	 is	not	
currently	a	suitable	approach.		




It	was	 identified	 that	 an	overall	 sense	of	management	 commitment	 to	 the	 self-inspection	
programme,	and	continuous	improvement	in	general,	may	serve	as	an	alternative	and	more	
realistic	approach	to	demonstrating	PQS	effectiveness	through	self-inspection.			
The	 importance	 of	 management	 commitment	 cannot	 be	 underestimated.	 	 	 Senior	
management	 set	 the	 tone	 for	 the	 quality	 culture	 of	 an	 organisation,	 along	 with	
implementing	 and	 providing	 the	 landscape	 for	 adhering	 to	 the	 quality	 policy.	 	 Therefore,	
success	of	the	self-inspection	programme,	risk-based	decision	making	and	an	effective	PQS	
is	 entirely	 underpinned	 by	management	 commitment	 and	management	 review.	 	 Indeed,	
Self-inspection	cannot	be	a	useful	 tool	 in	 the	demonstration	of	PQS	effectiveness	without	
management	 commitment.	 This	 should	 not	 just	 be	 seen	 as	 important	 for	 regulatory	
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a	 strong	 focus	on	 self-inspection.	 This	 is	 evidenced	by	 the	 lack	of	 update	 to	Chapter	 9	of	
EudraLex	Volume	4,	and	the	 interviews	conducted.	 	Naturally,	when	resources	are	 limited,	
pharmaceutical	 companies	will	 focus	 on	 those	 activities	 that	 add	 value	 or	 are	 seen	 to	 be	
requirements,	 whereas	when	 it	 comes	 to	 activities	 such	 as	 self-inspection	 they	may	 only	
perform	enough	to	achieve	compliance	as	this	is	all	the	regulator	looks	for.		
However,	 it	could	be	argued	that	pharmaceutical	companies	should	take	a	more	proactive	
approach	 in	 improving	 their	 self-inspection	programmes	and	demonstrating	 this	 to	health	
authorities.	 But	 in	 practice,	 this	 is	 only	 going	 to	 be	 worthwhile	 if	 there	 is	 a	 beneficial	
outcome.	 	 While	 there	 are	 paradigm	 changes	 coming,	 particularly	 with	 ICH	 Q12	 and	
research	 conducted	 by	 Ramnarine	 et	 al.	 (Ramnarine	 et	 al.,	 2020),	 the	 reality	 of	 reduced	
regulatory	oversight	or	regulatory	flexibility	has	not	yet	been	reached.		This	is	not	only	going	













To	 achieve	 the	 objectives	 envisioned	 by	 ICH	 Q8,	 Q9,	 Q10	 and	 Q12,	 an	 effective	
pharmaceutical	quality	system	 is	essential.	 	The	two	enablers	of	 the	PQS	according	to	 ICH	








their	 quality	 systems	 through	 various	means,	 the	 next	 step	 is	 capturing	 that	 information.		
Product	Quality	Reviews,	for	example,	tell	a	significant	story	about	the	PQS,	 if	appropriate	




The	 research	 presented	 in	 this	 paper	 aimed	 to	 determine	 how	 self-inspection	 could	 be	
better	utilised	in	demonstrating	PQS	effectiveness.		A	QRM	approach	to	developing	the	self-
inspection	process	was	proposed,	along	with	checklists	for	the	four	PQS	elements	and	the	
self-inspection	 process	 itself.	 	 These,	 when	 used	 in	 conjunction	 with	 one	 another	 and	
adapted	 to	 suit	 the	 size	 and	 complexity	 of	 the	 organisation,	 	 could	 be	 useful	 in	
21
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demonstrating	 that	 QRM	 is	 embedded	 across	 all	 processes	 within	 the	 PQS,	 and	 that	
emphasis	 is	 placed	 on	 continuous	 improvement.	 	 Together,	 this	 should	 serve	 to	 show	
regulators	that	the	PQS	is	effective	and	may	contribute	towards	achieving	the	ultimate	goal	
of	 regulatory	 relief.	 	However,	 the	 success	of	 such	an	approach	depends	on	management	
commitment.	 	 Management	 underpin	 the	 quality	 culture	 at	 the	 site,	 with	 management	
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